Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome

被引:53
|
作者
Baroutis, G [1 ]
Kaleyias, J [1 ]
Liarou, T [1 ]
Papathoma, E [1 ]
Hatzistamatiou, Z [1 ]
Costalos, C [1 ]
机构
[1] Gen Dist Hosp Alexandra, Dept Neonatal Med, Athens, Greece
关键词
surfactant; respiratory distress syndrome; Alveofact; Poractant; Beractant;
D O I
10.1007/s00431-002-1144-0
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The aim of the study was to compare the treatment regimen of three natural surfactants of different extraction and formulation (Alveofact [Surfactant A = SA], Poractant [Surfactant B = SB] and Beractant [Surfactant C = SC]) in neonatal respiratory distress syndrome (RDS). Premature infants of less than or equal to32 weeks' gestation with birth weight of less than or equal to2,000 g and with established RDS requiring artificial ventilation with a FiO2 greater than or equal to0.3 were randomly assigned to receive at least two doses of SA, SB or SC (100 mg/kg per dose). Infants who remained dependent on artificial ventilation with a FiO2 greater than or equal to0.3 received up to two additional doses. There were no differences among the groups regarding the necessity for more than two doses. The SA and the SB groups spent fewer days on a ventilator (p-value SA/SB 0.7, SA/SC 0.05, SB/SC 0.043) compared with the SC group, needed fewer days of oxygen administration (p-value SA/SB 0.14, SA/SC 0.05, SB/SC 0.04) and spent fewer days in hospital (p-value SA/SB 0.65, SA/SC 0.04, SB/SC 0.027). There were no statistically significant differences in the incidence of mortality, chronic lung disease, air leaks, necrotising enterocolitis, retinopathy of prematurity and intraventricular haemorrhage among the three groups. Conclusion: the Alveofact and Poractant groups spent fewer days on the ventilator, needed fewer days of oxygen administration and spent fewer days in hospital compared with the Beractant group but no differences were observed among the three groups with regards to mortality and morbidity.
引用
收藏
页码:476 / 480
页数:5
相关论文
共 50 条
  • [21] A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome
    Malloy, CA
    Nicoski, P
    Muraskas, JK
    ACTA PAEDIATRICA, 2005, 94 (06) : 779 - 784
  • [22] Choosing a Right Surfactant for Respiratory Distress Syndrome Treatment
    Ramanathan, Rangasamy
    NEONATOLOGY, 2009, 95 (01) : 1 - 5
  • [23] Effects of surfactant treatment in late preterm infants with respiratory distress syndrome
    Dani, Carlo
    Mosca, Fabio
    Vento, Giovanni
    Tagliabue, Paolo
    Picone, Simonetta
    Lista, Gianluca
    Fanos, Vassilios
    Pratesi, Simone
    Boni, Luca
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2018, 31 (10) : 1259 - 1266
  • [24] THE EFFECTS OF ANTENATAL CORTICOSTEROIDS AND SURFACTANT REPLACEMENT ON NEONATAL RESPIRATORY DISTRESS SYNDROME
    Heljic, Suada
    Maksic, Hajrija
    Kalkan, Ismeta
    Krdalic, Belma
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2009, 9 (03) : 225 - 228
  • [25] A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome
    Arnold, C
    Adams, E
    Vollman, J
    Giebner, D
    Maurer, M
    Dreyer, G
    Bailey, L
    Anderson, M
    Mefford, L
    Beaumont, E
    Sutton, D
    Puppala, B
    Mangurten, HH
    Secrest, J
    Lewis, WJ
    Carteaux, P
    Bednarek, F
    Welsberger, S
    Gosselin, R
    Pantoja, AF
    Belenky, A
    Campbell, P
    Patole, S
    Duenas, M
    Kelly, M
    Alejo, W
    Lewallen, P
    DeanLieber, S
    Hanft, M
    Ferlauto, J
    Newell, RW
    Bagwell, J
    Levine, D
    Lipp, RW
    Harkavy, K
    Vasa, R
    Birenbaum, H
    Broderick, KA
    Santos, AQ
    Long, BA
    Gulrajani, M
    Stern, M
    Hopgood, G
    Hegyi, T
    Alba, J
    Christmas, L
    McQueen, M
    Nichols, N
    Brown, M
    Quissell, BJ
    PEDIATRICS, 1996, 97 (01) : 1 - 6
  • [26] Surfactant Treatment Threshold during NCPAP for the Treatment of Preterm Infants with Respiratory Distress Syndrome
    Dani, Carlo
    AMERICAN JOURNAL OF PERINATOLOGY, 2016, 33 (10) : 925 - 929
  • [27] Comparison of efficacy and safety of two available natural surfactants in Iran, Curosurf and Survanta in treatment of neonatal respiratory distress syndrome: A randomized clinical trial
    Najafian, Bita
    Karimi-Sari, Hamidreza
    Khosravi, Mohammad Hossein
    Nikjoo, Niloofar
    Amin, Sobhan
    Shohrati, Majid
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2016, 3 : 55 - 59
  • [28] High-versus low-threshold surfactant retreatment for neonatal respiratory distress syndrome
    Kattwinkel, J
    Bloom, BT
    Delmore, P
    Glick, C
    Brown, D
    Lopez, S
    Willett, L
    Egan, EA
    Conaway, M
    Patrie, J
    PEDIATRICS, 2000, 106 (02) : 282 - 288
  • [29] Comparison of the Efficacy of Three Natural Surfactants in Preterm Turkish Newborns with Respiratory Distress Syndrome
    Yilmaz, Fatma Hilal
    Tarakci, Nuriye
    Gultekin, Nazli Dilay
    Yucel, Mehmet
    Kececi, Ramazan
    Ozturk, Elif Nur Yildirim
    Altunhan, Huseyin
    JOURNAL OF PEDIATRIC RESEARCH, 2021, 8 (02) : 124 - 130
  • [30] Nasal CPAP and surfactant for treatment of respiratory distress syndrome and prevention of bronchopulmonary dysplasia
    Verder, Henrik
    Bohlin, Kajsa
    Kamper, Jens
    Lindwall, Robert
    Jonsson, Baldvin
    ACTA PAEDIATRICA, 2009, 98 (09) : 1400 - 1408